Cover Image
市場調查報告書

Zedira GmbH的產品平台分析

Zedira GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318940
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Zedira GmbH的產品平台分析 Zedira GmbH - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 29 Pages
簡介

Zedira GmbH是生物製藥企業,正在從事研究開發及診斷用試劑的製造·銷售,及候選藥物的開發等。該公司產品的谷氨酰胺轉胺酶常用於生理學的流程研究中。

本報告提供Zedira GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Zedira GmbH的基本資料

  • Zedira GmbH概要
  • 主要資訊
  • 企業資料

Zedira GmbH:R&D概要

  • 主要的治療範圍

Zedira GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Zedira GmbH:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式
  • 開發階段不明的產品
    • 開發階段不明的產品/聯合治療模式

Zedira GmbH:藥物簡介

  • ZED-101
  • ZED-1098
  • ZED-1219
  • ZED-1301
  • ZED-754
  • Small Molecules to Inhibit Factor XIII for Thrombosis

Zedira GmbH:開發平台分析

Zedira GmbH:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07864CDB

Summary

Global Markets Direct's, 'Zedira GmbH - Product Pipeline Review - 2015', provides an overview of the Zedira GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zedira GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zedira GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zedira GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zedira GmbH's pipeline products

Reasons to buy

  • Evaluate Zedira GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zedira GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zedira GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zedira GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zedira GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zedira GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zedira GmbH Snapshot
    • Zedira GmbH Overview
    • Key Information
    • Key Facts
  • Zedira GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Zedira GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Zedira GmbH - Pipeline Products Glance
    • Zedira GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Zedira GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Zedira GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Zedira GmbH - Drug Profiles
    • ZED-1227
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Factor XIII for Thrombosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1219
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-754
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zedira GmbH - Pipeline Analysis
    • Zedira GmbH - Pipeline Products by Target
    • Zedira GmbH - Pipeline Products by Molecule Type
    • Zedira GmbH - Pipeline Products by Mechanism of Action
  • Zedira GmbH - Recent Pipeline Updates
  • Zedira GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zedira GmbH, Key Information
  • Zedira GmbH, Key Facts
  • Zedira GmbH - Pipeline by Indication, 2015
  • Zedira GmbH - Pipeline by Stage of Development, 2015
  • Zedira GmbH - Monotherapy Products in Pipeline, 2015
  • Zedira GmbH - Out-Licensed Products in Pipeline, 2015
  • Zedira GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Zedira GmbH - Phase I, 2015
  • Zedira GmbH - Preclinical, 2015
  • Zedira GmbH - Discovery, 2015
  • Zedira GmbH - Unknown, 2015
  • Zedira GmbH - Pipeline by Target, 2015
  • Zedira GmbH - Pipeline by Molecule Type, 2015
  • Zedira GmbH - Pipeline Products by Mechanism of Action, 2015
  • Zedira GmbH - Recent Pipeline Updates, 2015

List of Figures

  • Zedira GmbH - Pipeline by Top 10 Indication, 2015
  • Zedira GmbH - Pipeline by Stage of Development, 2015
  • Zedira GmbH - Monotherapy Products in Pipeline, 2015
  • Zedira GmbH - Pipeline by Top 10 Target, 2015
  • Zedira GmbH - Pipeline by Top 10 Molecule Type, 2015
  • Zedira GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top